Congenital Heart Disease (CHD) Market Study Highlights How Industry Demand Is Evolving

Exploring the future of the congenital heart disease (CHD) market reveals promising growth and innovation. As medical technologies advance and awareness rises, this sector is poised to undergo significant development. This overview highlights anticipated market expansion, leading companies, emerging trends, and detailed segmentation to provide a comprehensive understanding of the CHD landscape.

Strong Market Growth Expected in the Congenital Heart Disease (CHD) Market by 2030
The congenital heart disease market is projected to experience substantial growth in the coming years, reaching a valuation of $7.27 billion by 2030. This expansion is driven by a robust compound annual growth rate (CAGR) of 8.1%. Several key factors contribute to this rise, including progress in minimally invasive cardiology techniques, enhanced imaging and diagnostic tools, a growing population of adults living with CHD, the increase in specialized cardiac care centers, and higher healthcare investments globally. Additional trends likely to influence this growth encompass broader prenatal and neonatal screening efforts, greater use of catheter-based interventions, the development of care programs targeting both pediatric and adult patients, improved survival rates, and the adoption of multidisciplinary approaches for long-term disease management.

The congenital heart disease (chd) market size has grown strongly in recent years. It will grow from $4.85 billion in 2025 to $5.32 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to high prevalence of structural birth defects, limited early diagnostic capabilities, reliance on open-heart surgery, high infant mortality rates, concentration of care in tertiary hospitals.

Download a free sample of the congenital heart disease (chd) market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15545&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Key Factors Catalyzing Growth in the Congenital Heart Disease Market
Advancements in minimally invasive cardiology procedures have significantly improved treatment options, making interventions less risky and more accessible. This technological progress is a major driver behind the expanding CHD market.
Meanwhile, expanding healthcare infrastructure, such as the rise of specialized cardiac centers, is enhancing patient access to focused care. Increased investments in healthcare systems worldwide further support this trend, facilitating better diagnosis and management of congenital heart conditions.

Leading Companies Shaping the Congenital Heart Disease Market Landscape
Several prominent organizations dominate the CHD market, including Abbott Laboratories, Medtronic, Siemens Healthineers, Philips Healthcare, Roche Diagnostics International Ltd., Boston Scientific Corp., Laboratory Corporation of America Holdings (LabCorp), Terumo Corporation, Mindray Medical International Limited, Canon Medical Systems Corporation, Masimo Corporation, Carestream Health, Schiller AG, BPL Medical Technologies, Bionet America Inc., Edwards Lifesciences Corporation, GE Healthcare, BIOTRONIK SE & Co KG, W L Gore & Associates Inc, Cook Medical, Lepu Medical Technology Co Ltd, Getinge AB, Merit Medical Systems Inc, Eurocor Tech GmbH, and Braile Biomedica.
In May 2024, Novartis Healthcare Private Limited from Switzerland formed a partnership with Ayala Healthcare Holdings, Inc. (AC Health) in the Philippines to launch an Integrated Cardiovascular and Cancer Care initiative. This collaboration aims to enhance access to cutting-edge treatments for breast cancer, heart failure, and high cholesterol, combining Novartis's innovation with AC Health's expertise in generic pharmaceuticals.

View the full congenital heart disease (chd) market report:
https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Innovations and Trends Transforming the CHD Market
Non-surgical heart valves, known as transcatheter valves, are gaining attention as a less invasive treatment option that improves patient outcomes and quality of life. These devices avoid the need for traditional open-heart surgery, representing a significant leap forward in care.
A notable example is Medtronic's Harmony Transcatheter Pulmonary Valve (TPV) System, reintroduced in February 2023 after receiving FDA approval in 2021. This minimally invasive valve is designed to treat patients with congenital heart disease who have native or surgically repaired right ventricular outflow tract anomalies. The system provides a first-of-its-kind, non-surgical solution for severe pulmonary valve regurgitation and highlights Medtronic's ongoing dedication to advancing CHD treatment.

Detailed Segmentation of the Congenital Heart Disease (CHD) Market
The CHD market is segmented comprehensively in this report by:
- Type: Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, and Other Types
- Diagnosis Methods: Electrocardiogram, Chest X-ray, Echocardiogram, Transesophageal Echocardiogram, Pulse Oximetry, Exercise Stress Test, Cardiac CT Scan or MRI, Cardiac Catheterization, and Other Diagnostic Procedures
- Treatment Approaches: Interventional Cardiology, Cardiac Surgery, Telemedicine, Medication Management, and Lifestyle Modifications
- Age Groups: Infants, Children, Adolescents, and Adults
- Application Settings: Hospitals and Clinics, Diagnostic Centers, Ambulatory Surgical Centers, and Research and Academic Institutions

Further subcategories cover specific conditions such as:
- Heart Valve Defects including Aortic Valve Stenosis, Pulmonary Valve Stenosis, Mitral Valve Prolapse, Tricuspid Valve Defects, and Valve Regurgitation
- Heart Wall Defects like Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), Atrioventricular Septal Defect (AVSD), Hypoplastic Left Heart Syndrome (HLHS), and Tetralogy of Fallot (TOF)
- Blood Vessel Defects covering Coarctation of the Aorta, Patent Ductus Arteriosus (PDA), Pulmonary Artery Stenosis, Transposition of the Great Arteries (TGA), and Truncus Arteriosus
- Other Types including Single Ventricle Defects, Ebstein's Anomaly, Total Anomalous Pulmonary Venous Return (TAPVR), Coronary Artery Anomalies, and Pulmonary Venous Obstruction

This detailed segmentation provides a thorough understanding of the diverse components within the congenital heart disease market.

Our 2026 market reports now include enhanced strategic insights through:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.